Navigation Links
Increased Dosage of Needle-Free Erectile Dysfunction Medication TriMix-gel Now Available through KRS Global Biotechnology
Date:5/7/2013

BOCA RATON, Fla., May 7, 2013 /PRNewswire/ -- TriMix Laboratories, LLC and KRS Global Biotechnology, INC today announced the availability of TriMix-gel® in a 2000 microgram dose.  The joint developmental effort is the result of physicians and patients asking if it was possible for TriMix-gel to come in an increased dosage.  After development and testing, the new dosage is available immediately from KRS Global Biotechnology on the prescription of a licensed physician. 

TriMix-gel was introduced at the American Urological Association's World Conference.  Since then, thousands of American physicians have prescribed TriMix-gel for patients who cannot tolerate self-injection with a needle or who failed on PDE5 Inhibitors such as Viagra, Levitra or Cialis (J. Urol. 179 (4): 431, 2008).

Each individual dose of TriMix-gel is shipped to the patient in an ED-GEL™ applicator.  This novel, patent pending applicator, stores, mixes and applies the medicine without the patient having to self-inject himself with a needle.  Three short videos are available at www.TriMix-gel.com.  These videos are important in helping doctors and patients understand how to order TriMix-gel and how to apply the medicine.

TriMix Laboratories LLC develops innovative products toward the clinical advancement of urology.  For more information, visit www.TriMix-gel.com .  KRS Global Biotechnology is a recognized leader in pharmaceutical compounding, helping Physicians and Veterinarians with medicine precisely customized for each individual patient.  KRS maintains state licenses and dispenses compounded medications in almost all states. For more information, visit www.GBTBIO.com .

The information contained herein is general in nature and is intended for use only as an informational aid. It does not cover all possible uses, actions, precautions, side effects, or interactions of the products shown, nor is the information intended as medical advice or diagnosis for individual health problems. TriMix-gel has not been evaluated by the Food and Drug Administration (FDA) and is not made under GMP requirements. It is compounded in a licensed compounding pharmacy. The compound is for the use of an individual patient who has been prescribed TriMix-gel by a licensed physician.  The information contained herein is not intended for making an evaluation as to suitability, risks or benefits. Before taking any action, consult your Physician.

Contact: T.J. Harkins
TriMix Laboratories
800-572-3330

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE TriMix Laboratories
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Amgens First Quarter 2013 Revenues Increased 5 Percent To $4.2 Billion And Adjusted Earnings Per Share (EPS) Increased 22 Percent To $1.96
2. Covance Expands Singapore Central Laboratory by 50 Percent to Meet Clients Increased Asia Pacific Focus
3. Hemodialysis Patient Share for Sanofis Ferrlecit Increased Significantly in the First Quarter of 2013 Compared to the Previous Quarter
4. Valeant Pharmaceuticals And Obagi Medical Products Agree On An Increased Offer Price Of $24.00 Per Share In Cash
5. Niacin Causes Serious Unexpected Side-effects, but no Worthwhile Benefits, for Patients who are at Increased Risk of Heart Attacks and Strokes
6. Sigma-Aldrich Reports Record Full Year 2012 Results. Reports Q4 2012 Diluted EPS Of $0.96. Q4 2012 Sales Increased 7%. Full Year 2012 Adjusted Diluted EPS Was $3.85. Expects Full Year 2013 Adjusted Diluted EPS To Increase To $4.10 - $4.20.
7. Amgens Full Year 2012 Revenues Increased 11 Percent To $17.3 Billion And Adjusted Earnings Per Share (EPS) Increased 22 Percent To $6.51
8. Murray Dental Laboratory Deploys Jensen Dental CAD/CAM Solution for Increased Productivity, Higher Sales and More Consistent Restorations
9. Medbox, Inc. Announced Increased Funding for Corporate Giving Program in 2013
10. DePuy Settlement Funding And Transvaginal Mesh Capital Increased At Legal-Bay
11. Artificial disc brings increased mobility and rapid recovery to patients suffering chronic neck pain in the Midwest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... , Oct. 4, 2017 ... single-use, self-contained, illuminating medical devices, today announced regulatory ... Health Surveillance Agency (or Agência Nacional de Vigilância ... first single-use, cordless surgical retractor with integrated LED ... optimal access, illumination and exposure of a tissue ...
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile app ... struggle to reverse the tide of prescription drug addiction. The ... their medicine intake and stepping down their dosage in a ... launch in December 2017; the first 100,000 people to sign ... at http://www.rebound-solution.com/ ...
(Date:9/25/2017)... Sept. 25, 2017   Montrium , an ... solutions, today—from the IQPC Trial Master Files & ... NL)—announced that EastHORN Clinical Services has selected ... and TMF management. EastHORN, a leading European contract ... to increase transparency to enable greater collaboration with ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills ... specialty vendors and unique items from across the nation, this holiday-themed event will raise ... offered by the VNA. The boutique will be open Saturday, November 4 (10:00 ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... system that we intend to develop to enable prevention of a major side ... severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA ...
(Date:10/12/2017)... Mich. (PRWEB) , ... October 12, 2017 , ... ... has been named one of Michigan’s 2017 Best and Brightest in Wellness® by ... Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. to ...
Breaking Medicine News(10 mins):